Pulmonary arterial hypertension is a rare form of pulmonary hypertension that poses diagnostic challenges and often comes with a delayed diagnosis.
Pulmonary hypertension (PH) is organized into 5 clinical groups, and a review published Wednesday in The New England Journal of Medicine discussed the pathophysiology of pulmonary arterial hypertension (PAH), a more-complicated and rare subset of PH.
The incidence of PH worldwide is about 1%, with many of those affected living in developing countries and thus without treatment. PH complicates other lung diseases such as chronic obstructive pulmonary disease, as well as blood diseases and viral infections.
PAH, in which right ventricular dysfunction leads to heart failure, affects 25 individuals per 1 million people in Western countries, according to the author. Most of them are women and the most severe cases happen in the elderly. PAH, belonging to group 1 of PH diseases, is marked by several shared features that result in luminal narrowing or the complete blockage of small vessels in the lungs:
It is unclear what leads to the remodeling, “but endothelial dysfunction induced by shear stress, hypoxia, autoimmune phenomena, viral infections, drugs and toxins, or genetic alterations may initiate the process of excess vasoconstriction, inflammation, and uncontrolled cellular growth,” the author wrote. Inflammation may also play a role.
Another facet of PAH that also remains unclear is the process that creates remodeling of the right ventricle, the function of which is key to clinical outcomes and survival in PH. As pulmonary vascular pressure increases, the right ventricle undergoes hypertrophy, chamber dilatation, fat deposition, fibrosis, and metabolic shifts.
Remodeling may be adaptive or maladaptive. The current diagnostic standard for testing right ventricle function (pressure–volume loop technology with a high-fidelity conductance catheter) is invasive. Noninvasive measures, such as echocardiography or cardiac MRI, have not yet been formally validated but have predicted outcomes in some research.
PAH symptoms are nonspecific, including exertional dyspnea, fatigue, chest pain, fluid retention, and fainting. Risk factors include HIV, connective tissue disease, liver disease, pediatric PH, and a history of exposure to illicit drugs or toxins.
Transthoracic echocardiography (TTE) can not only measure the prevalence, cause, and severity of PAH but also identify left ventricular systolic or diastolic dysfunction and valvular abnormalities, which would indicate group 2 PH.
There are 3 signaling pathways targeted for PAH treatment: endothelin-1, prostacyclin (PGI2), and nitric acid. Three therapies are approved for the endothelin-1 pathway, including macitentan, bosentan, and ambrisentan; 4 therapies for the PGI2 pathway (selexipag, eporostenol, treprostinil, iloprost); and 3 for the nitricoxide pathway (riociguat, sildenafil, and taalfil).
The PAH field advanced more than 20 years ago with the discovery of a genetic predisposition through heterozygous mutations in the BMPR2 gene, a member of the transforming growth factor β (TGF-β) superfamily of receptors. At least 16 other genes have been identified in heritable PAH, including ACVRL1, SMAD1, SMAD4, SMAD9, CAV1, and others.
Reference
Hassoun PM. Pulmonary arterial hypertension. N Engl J Med. 2021;385:2361-2376. doi:10.1056/NEJMra2000348
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More